GHRP-2 and GHRP-6 Research: Growth Hormone Releasing Peptide Pharmacology

GHRP-2 and GHRP-6 are synthetic hexapeptide GHS-R1a agonists representing the first and second generation of synthetic growth hormone secretagogues. Their development history — and their pharmacological limitations compared to more selective later compounds like Ipamorelin — makes them valuable reference compounds for understanding GH secretagogue pharmacology.

Historical Context: The GHRP Discovery

The growth hormone releasing peptide family originated from structure-activity relationship studies on met-enkephalin (Tyr-Gly-Gly-Phe-Met) at Tulane University by Cyril Bowers and colleagues beginning in the late 1970s. Working from the observation that some enkephalin analogues released GH, Bowers' group synthesised increasingly potent GH-releasing peptides, culminating in GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) in 1984 — the foundational growth hormone releasing peptide from which all subsequent GHRPs were derived.

The molecular target of GHRP-6 and related compounds was unknown for 15 years until the identification and cloning of GHS-R1a (growth hormone secretagogue receptor 1a) in 1996, followed by the subsequent identification of ghrelin as its natural endogenous ligand in 1999.

GHRP-6: The Original

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the archetypal GHRP and has been used in published research since 1984, providing the most extensive literature of any GHRP. Key pharmacological features:

GHS-R1a activation. Full agonist at GHS-R1a with high potency. The D-Trp2 residue is essential for GHS-R1a binding — replacement with L-Trp or other amino acids dramatically reduces potency, establishing D-Trp2 as a critical pharmacophore element.

Appetite stimulation. GHRP-6 produces robust appetite stimulation through GHS-R1a in the hypothalamic arcuate nucleus. Arcuate nucleus neurons expressing GHS-R1a include AgRP/NPY neurons whose activation drives food intake. This appetite effect is well characterised in published rodent research using GHRP-6 as a tool compound.

ACTH and cortisol. Modest ACTH/cortisol stimulation accompanies GH release with GHRP-6, making it less clean as a selective GH research tool.

GHRP-2: Improved Selectivity

GHRP-2 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) represents the next developmental step. Key changes from GHRP-6:

The His1 of GHRP-6 is replaced with D-Ala1 in GHRP-2. The D-Trp2 of GHRP-6 is replaced by D-beta-Naphthylalanine (D-beta-Nal), which provides stronger GHS-R1a binding due to larger aromatic surface area. These modifications increased GHS-R1a potency and partially improved selectivity, though GHRP-2 still produces significant ACTH and prolactin release compared to Ipamorelin.

Comparison with Ipamorelin

The development of Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) by Novo Nordisk in 1998 addressed the selectivity limitations of GHRP-2 and GHRP-6. Ipamorelin produces equivalent GHS-R1a-mediated GH release with minimal ACTH, prolactin, aldosterone, or appetite stimulation — making it pharmacologically cleaner for research requiring isolated GH axis effects.

For research requiring isolated GH axis stimulation, Ipamorelin is the preferred tool. GHRP-2 and GHRP-6 remain valuable as reference compounds for characterising the selectivity improvements of newer GHRPs, and for research specifically studying appetite signalling (GHRP-6) or comparative GHS-R1a pharmacology.

Published Research References

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related research peptides: Ipamorelin | CJC-1295 + Ipamorelin Blend | CJC-1295 (No DAC)
View GHRP-2 | View GHRP-6

GHRP Development History: From Enkephalin to Ipamorelin

The GHRP family's development began from an unexpected observation: certain enkephalin analogues could release GH from pituitary cells. Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin normally activate opioid receptors but have minimal GH-releasing activity. Cyril Bowers at Tulane University discovered in the late 1970s that specific structural modifications to enkephalin analogues produced compounds with potent GH-releasing activity at non-opioid receptors — the discovery that eventually led to GHRP-6 in 1984.

The key modifications that converted enkephalin to GHRP were: substitution of D-Trp for L-Trp at position 2 (D-configuration provides protease resistance and alters receptor selectivity); addition of Ala at position 3; and replacement of Phe-Met at positions 4-5 with Trp-D-Phe-Lys (increasing hydrophobicity and adding a positively charged Lys). The resulting His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 structure (GHRP-6) activated a receptor distinct from opioid receptors — later identified as GHS-R1a after the cloning by Howard et al. (Science, 1996).

GHRP-2 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) was the next development iteration, replacing His1 with D-Ala1 and D-Trp2 with D-beta-Naphthylalanine, achieving higher GHS-R1a potency. Ipamorelin (Raun et al., 1998) then introduced the Aib1 modification and the Lys-NH2 C-terminal amide to achieve GHS-R1a selectivity without ACTH cross-reactivity.

NPY/AgRP System and GHRP-6 Appetite Research

GHRP-6's appetite-stimulating effect via hypothalamic NPY/AgRP neurons makes it a valuable research tool for studying the ghrelin-NPY axis. GHS-R1a-expressing arcuate nucleus neurons include the AgRP/NPY orexigenic population that promotes feeding behaviour. GHRP-6 activation of GHS-R1a on these neurons stimulates NPY release (which acts at Y1/Y5 receptors on PVN neurons to drive feeding) and AgRP release (which antagonises MC4R, removing anorexigenic tone).

Research paradigms examining GHRP-6 appetite stimulation use hypothalamic slice preparations to measure NPY neuron firing rates by electrophysiology, in situ hybridisation or qPCR for NPY and AgRP mRNA expression following GHRP-6 treatment, and food intake measurement in satiated rodent models where the orexigenic effect is measurable above baseline food intake.

Comparing GHRP-6 (strong appetite stimulation through NPY/AgRP) with Ipamorelin (minimal appetite effect despite equivalent GHS-R1a activation) allows researchers to examine what structural features of GHRP-6 are responsible for the appetite-stimulating activity — the orexigenic effect that Ipamorelin lacks despite equivalent GH-releasing potency.

Frequently Asked Questions

What is the significance of GHRP-2's other name, Pralmorelin?
Pralmorelin is the INN (International Nonproprietary Name) assigned to GHRP-2, reflecting its investigation as a pharmaceutical compound. Pralmorelin reached clinical trials as a GH stimulation test agent — similar to Sermorelin's clinical use as the Sermorelin stimulation test for GH reserve assessment. Published pharmacokinetic data from Pralmorelin clinical studies provides reference parameters for in vitro research using GHRP-2. The INN nomenclature indicates that GHRP-2 underwent sufficient development for regulatory agencies to assign a formal drug name, reflecting its well-characterised pharmacological profile.

Why are GHRP-2 and GHRP-6 still relevant research tools given that the more selective Ipamorelin is available?
The GHS-R1a research toolkit benefits from compounds with different selectivity profiles. GHRP-6 and GHRP-2's off-target effects (ACTH, prolactin, appetite) are research tools themselves when those systems are the research focus. For example: studying the GHS-R1a/HPA axis interaction (how GHS-R1a activation influences cortisol) requires GHRP-2 (which has this off-target activity) rather than Ipamorelin (which does not). Historical comparison with GHRP-6 and GHRP-2 data allows new findings with Ipamorelin to be contextualised within the extensive published GHRP literature spanning 40 years.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide

Practical Research Notes: GHRP-2 and GHRP-6 Side-by-Side

For researchers running GHRP-2 and GHRP-6 in parallel experiments to compare selectivity profiles, the following practical points ensure consistent experimental design:

Matched molar concentrations: GHRP-2 (MW 817.94 g/mol) and GHRP-6 (MW 873.03 g/mol) have similar but not identical molecular weights. For side-by-side comparison at equivalent receptor occupancy, prepare solutions at matched molar concentrations (e.g., both at 100 nM) rather than matched mass concentrations (mg/mL).

GH secretion timing: Both GHRP-2 and GHRP-6 stimulate GH release from pituitary cells with peak GH at approximately 15-30 minutes post-administration in animal models. For in vitro pituitary cell experiments, collect medium at 15-minute intervals for the first hour to capture the full secretion curve.

ACTH cross-reactivity monitoring: When using GHRP-2 or GHRP-6 in intact animal research models, measure ACTH and cortisol alongside GH to characterise the off-target adrenocortical stimulation. Comparing ACTH/GH ratios for GHRP-2, GHRP-6, and Ipamorelin in the same model provides direct selectivity comparison data for your specific research system.

Storage: Both GHRP-2 and GHRP-6 are stable lyophilised at -20°C. Reconstituted solutions in bacteriostatic water are stable at 4°C for 2-3 weeks. Protect from light to prevent potential photodegradation of the tryptophan residue present in GHRP-6.